Search Results 281-290 of 23023 for Phase

1. Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer - Mayo Clinic

   Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer · More about research at Mayo Clinic · Mayo Clinic Footer.

2. A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma - Mayo Clinic

   A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma · Overview · Participation eligibility.

3. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC - Mayo Clinic

   The main purpose of the study is to evaluate safety and effectiveness of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of ...

4. A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral Ixazomib (MLN9708) plus Lenalidomide and Dexamethasone versus ...

5. A Study to Compare Circadian Phase in Patients with Wet Macular Degeneration to Controls Without Ocular Pathology - Mayo Clinic

   A Study to Compare Circadian Phase in Patients with Wet Macular Degeneration to Controls Without Ocular Pathology · Overview · Participation eligibility.

6. A Phase 3 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of L606 in Subjects With PAH - Mayo Clinic

   The current Phase 3 study will help determine the short-term and long-term safety and tolerability of L606 in this patient population. The study will also ...

7. A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure - Mayo Clinic

   A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure. Print details.

8. Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). - Mayo Clinic

   Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Print ...

9. Mayo Clinic installs first magnetic nanoparticle hyperthermia system for cancer research in the US

   New Phase Ltd. manufactures both the hyperthermia machine and the nanoparticles. Mayo Clinic installed the machine within the Radiation Oncology Department ...

10. Phase IIB Study Of PHENOGENE-1A (Cromolyn) As An Adjuvant Therapy In Mild To Moderate ALS - Mayo Clinic

    Phase IIB Study Of PHENOGENE-1A (Cromolyn) As An Adjuvant Therapy In Mild To Moderate ALS. Print details. Share; Facebook · Twitter.